Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company's stock.

Several other brokerages also recently commented on OMER. StockNews.com downgraded Omeros from a "hold" rating to a "sell" rating in a report on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Friday, January 17th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Omeros currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Down 4.1 %

Shares of NASDAQ:OMER traded down $0.30 during trading on Tuesday, hitting $7.06. 802,194 shares of the company were exchanged, compared to its average volume of 552,036. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60. The business's 50 day moving average is $8.56 and its 200-day moving average is $7.63. The company has a market capitalization of $409.93 million, a P/E ratio of -3.06 and a beta of 2.35.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same period last year, the company posted ($0.15) earnings per share. As a group, sell-side analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

A number of large investors have recently bought and sold shares of the business. Nomura Holdings Inc. grew its stake in Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after purchasing an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Omeros during the 4th quarter worth approximately $1,488,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Omeros during the 4th quarter worth approximately $1,120,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Omeros during the 4th quarter worth approximately $1,033,000. Finally, Ancora Advisors LLC increased its stake in shares of Omeros by 1,036.4% in the 4th quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company's stock valued at $848,000 after acquiring an additional 78,250 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.